Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas (Q47727562)

30 June 2019

meta-analysis

0 references

title

Prognostic Power of a Tumor Differentiation Gene Signature for Bladder Urothelial Carcinomas (English)

1 reference

30 June 2019

author name string

Qianxing Mo

1

1 reference

30 June 2019

Fotis Nikolos

2

1 reference

30 June 2019

Fengju Chen

3

1 reference

30 June 2019

Zoe Tramel

4

1 reference

30 June 2019

Yu-Cheng Lee

5

1 reference

30 June 2019

Kazukuni Hayashi

6

1 reference

30 June 2019

Jing Xiao

7

1 reference

30 June 2019

Jianjun Shen

8

1 reference

30 June 2019

Keith Syson Chan

9

1 reference

30 June 2019

language of work or name

English

0 references

publication date

1 May 2018

1 reference

30 June 2019

Journal of the National Cancer Institute

published in

1 reference

30 June 2019

volume

110

1 reference

30 June 2019

issue

5

1 reference

30 June 2019

page(s)

448-459

1 reference

30 June 2019

Urothelial carcinoma of the bladder: definition, treatment and future efforts

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Decade in review-bladder cancer: international progress: from cytology to genomics.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Three differentiation states risk-stratify bladder cancer into distinct subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Normal and neoplastic urothelial stem cells: getting to the root of the problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

A molecular taxonomy for urothelial carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Comprehensive molecular characterization of urothelial bladder carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Independent component analysis uncovers the landscape of the bladder tumor transcriptome and reveals insights into luminal and basal subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, an

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Patterns of splice variant CD44 expression by normal human urothelium in situ and in vitro and by bladder-carcinoma cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Cytokeratin 14 as a marker of squamous differentiation in transitional cell carcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

KRT14 marks a subpopulation of bladder basal cells with pivotal role in regeneration and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Uroplakins in urothelial biology, function, and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Stat3 activation in urothelial stem cells leads to direct progression to invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Self-renewal of pluripotent embryonic stem cells is mediated via activation of STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Defining progression in nonmuscle invasive bladder cancer: it is time for a new, standard definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Toll-like receptors and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

STATs in cancer inflammation and immunity: a leading role for STAT3

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Immune Checkpoint Blockade in Cancer Therapy: The 2015 Lasker-DeBakey Clinical Medical Research Award.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Immune Checkpoint Blockade in Cancer Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Combination cancer immunotherapy and new immunomodulatory targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Effects of PPAR agonists on proliferation and differentiation in human urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

A 17-gene stemness score for rapid determination of risk in acute leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

A basal stem cell signature identifies aggressive prostate cancer phenotypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Modeling precision treatment of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Omics and therapy - a basis for precision medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Blocking PGE2-induced tumour repopulation abrogates bladder cancer chemoresistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Molecular Pathways: Targeting Cancer Stem Cells Awakened by Chemotherapy to Abrogate Tumor Repopulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2FDJX243

Normal human urothelial cells in vitro: proliferation and induction of stratification.

21 January 2018

1 reference

12 December 2020

Cytokeratin expression patterns in normal and malignant urothelium: a review of the biological and diagnostic implications

1 reference

12 December 2020

Role of PPARgamma and EGFR signalling in the urothelial terminal differentiation programme

1 reference

12 December 2020

Linear models and empirical bayes methods for assessing differential expression in microarray experiments

1 reference

12 December 2020

Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJX243

1 reference

30 June 2019

PMCID

6279371

1 reference

30 June 2019

PubMed ID

29342309

1 reference

30 June 2019